These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16307177)

  • 1. Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.
    Ohkubo Y; Ueta A; Ando N; Ito T; Yamaguchi S; Mizuno K; Sumi S; Maeda T; Yamazaki D; Kurono Y; Fujimoto S; Togari H
    J Hum Genet; 2006; 51(2):118-123. PubMed ID: 16307177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
    Desta Z; Zhao X; Shin JG; Flockhart DA
    Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and functional characterization of new potentially defective alleles of human CYP2C19.
    Blaisdell J; Mohrenweiser H; Jackson J; Ferguson S; Coulter S; Chanas B; Xi T; Ghanayem B; Goldstein JA
    Pharmacogenetics; 2002 Dec; 12(9):703-11. PubMed ID: 12464799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.
    Ibeanu GC; Blaisdell J; Ferguson RJ; Ghanayem BI; Brosen K; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Goldstein JA
    J Pharmacol Exp Ther; 1999 Aug; 290(2):635-40. PubMed ID: 10411572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Misclassification of allele CYP2C19*10 as CY2C19*2 by a commonly used PCR-RFLP procedure.
    Rasmussen H; Werge T
    Genet Test; 2008 Mar; 12(1):57-8. PubMed ID: 18373404
    [No Abstract]   [Full Text] [Related]  

  • 6. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
    Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
    Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
    Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A
    Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.
    Tassaneeyakul W; Tawalee A; Tassaneeyakul W; Kukongviriyapan V; Blaisdell J; Goldstein JA; Gaysornsiri D
    Pharmacogenetics; 2002 Apr; 12(3):221-5. PubMed ID: 11927837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
    Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
    Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
    Brøsen K; de Morais SM; Meyer UA; Goldstein JA
    Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
    Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism].
    Lou YQ; Kuang TY
    Sheng Li Ke Xue Jin Zhan; 1995 Jan; 26(1):23-8. PubMed ID: 7604218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.
    Ibeanu GC; Blaisdell J; Ghanayem BI; Beyeler C; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Daly AK; Goldstein JA
    Pharmacogenetics; 1998 Apr; 8(2):129-35. PubMed ID: 10022751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.
    Kaneko A; Lum JK; Yaviong L; Takahashi N; Ishizaki T; Bertilsson L; Kobayakawa T; Björkman A
    Pharmacogenetics; 1999 Oct; 9(5):581-90. PubMed ID: 10591538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe.
    Masimirembwa C; Bertilsson L; Johansson I; Hasler JA; Ingelman-Sundberg M
    Clin Pharmacol Ther; 1995 Jun; 57(6):656-61. PubMed ID: 7781265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.
    Xie HG; Kim RB; Stein CM; Wilkinson GR; Wood AJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):402-8. PubMed ID: 10510153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.